TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02286245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focused Telephonic Medical Advice
Description: The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
Study: NCT02195180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY001
Study: NCT00822185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
Study: NCT02734290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
Study: NCT01914107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: real-time monitoring and instruction of cancer pain
Description: as description in arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard cancer pain care
Description: as description in arm
Study: NCT00717665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home blood pressure tele-management system.
Description: Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care.
Description: Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
Study: NCT03308214

Intervention type: DRUG
Intervention: Imipenem
Description: Imipenem 1.0 q 8h

Intervention type: DRUG
Intervention: Imipenem
Description: Imipenem 1.0 q 8h
Study: NCT03817190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107
Description: DS107 Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT02960009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
Study: NCT03417388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose potent statin
Description: The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-I (lisinopril) or ARB (losartan)
Description: Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Will be recommended to IMT women without contraindications or bleeding risk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Quality of Life Questionnaires will be obtained.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Questionnaires
Description: Quality of Life Questionnaires will be obtained.
Study: NCT00824863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole 2% foam
Description: topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
Study: NCT02978287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAVU Solution
Description: Tissue preservation solution for transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAVU Solution
Description: Tissue preservation solution for transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAVU Solution
Description: Tissue preservation solution for transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAVU Solution
Description: Tissue preservation solution for transplantation
Study: NCT00703547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK586529 capsules
Description: GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK586529 capsules
Description: GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK586529 tablets
Description: GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK586529 tablets
Description: GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
Study: NCT02195180

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT00703547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and capsules will be provided to subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and capsules will be provided to subjects.
Study: NCT00107458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Study: NCT00506090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser therapy
Description: Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser therapy
Description: Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pulsed dye laser therapy
Description: Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
Study: NCT00784511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 4000 IU/d

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: 1/d
Study: NCT02904057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse (+) Injectable Implant
Description: Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
Study: NCT01485315

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion
Description: One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion
Description: One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
Study: NCT00654277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ODT, 8 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: ODT, 8 mg, fasting conditions
Study: NCT01088009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: lamivudine, adefovir
Description: patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
Study: NCT04157946

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch).

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch).
Study: NCT01453842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet oil
Description: Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: Carrot and olive oil and 1½ g of paracetamol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carrot
Description: Carrot and 1½ g of paracetamol
Study: NCT02940171

Intervention type: PROCEDURE
Intervention: Early Excision of full thickness burn
Description: first excision surgery of full -thickness burn performed within 48 hours from burn injury

Intervention type: PROCEDURE
Intervention: Late Excision of full thickness burn
Description: first excision surgery of full -thickness burn performed after 48 hours from burn injury
Study: NCT04175093

Intervention type: DIAGNOSTIC_TEST
Intervention: asymmetric dimethylarginine
Description: measurement by ELISA of asymmetric dimethylarginine

Intervention type: DIAGNOSTIC_TEST
Intervention: asymmetric dimethylarginine
Description: measurement by ELISA of asymmetric dimethylarginine
Study: NCT02960009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HD-tDCS
Description: Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
Study: NCT04175093

Intervention type: DIAGNOSTIC_TEST
Intervention: asymmetric dimethylarginine
Description: measurement by ELISA of asymmetric dimethylarginine
Study: NCT01139281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract (GBE761)
Description: The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
Study: NCT02273843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D 3
Description: Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional-Dose Vitamin D 3
Description: Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
Study: NCT01901003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no premedication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline celluloses)
Study: NCT04217486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient will be shown a photograph of their knee at 2 weeks postop
Description: Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient will not be shown a photograph of their knee at 2 weeks postop
Description: Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
Study: NCT04076969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated educational session
Description: The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrated educational session
Description: The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
Study: NCT02203864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIBW2 component A
Description: BIBW2 without IL-2 secreting cell line

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIBW2 component B
Description: BIBW2 with IL-2 secreting cell line
Study: NCT02811939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dronabinol
Description: 20 mg capsule of Dronabinol will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dronabinol
Description: 20 mg capsule of Dronabinol will be administered orally
Study: NCT02195180

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
Description: oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
Study: NCT01153100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
Study: NCT04636476

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modified Nesbit's procedure and dorsal dartos flap
Description: Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
Study: NCT04777227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Description: 2% (20mg/ml) lidocaine solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological water injection
Description: 0.9% sterile sodium chloride water

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
Study: NCT02811939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pregnenolone
Description: 1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pregnenolone
Description: 1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Dronabinol
Description: Control: Placebo pill (no active cannabinoids) administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dronabinol
Description: Control: Placebo pill (no active cannabinoids) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pregnenolone
Description: Control: Placebo given sublingually (under the tongue)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pregnenolone
Description: Control: Placebo given sublingually (under the tongue)
Study: NCT02439112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly \>65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)
Study: NCT04347395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Bundle & Prevention
Description: The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
Study: NCT01076985

Intervention type: DRUG
Intervention: Lopinavir/ritonavir (Kaletra)
Description: Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Study: NCT02889094

Intervention type: OTHER
Intervention: Routine care
Description: Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
Study: NCT04777227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement
Description: A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
Study: NCT02195180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
Description: oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
Study: NCT03643562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrabetadex
Description: Administered via lumbar puncture (LP) and IT infusion
Study: NCT02353559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASE
Description: EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
Study: NCT00326612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
Study: NCT03611569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo - concentrate for solution for infusion, single dose
Study: NCT02809430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.